Javier R. Lama - Concepedia

Author

Javier R. Lama

Asociación Civil Impacta Salud y Educación ORCID

Also Known As

Balagopal, Ashwin, Carmen D. Zorrilla, Fernando Gonzales, Heath, Sonya L., Hogg, Evelyn, Ian McGowan, J Lama, J R Lama, J. R. Lama, JAVIER R. LAMA

205

Publications

14.4K

Citations

H-Index

Concepts

All Affiliations

Asociación Civil Impacta Salud y Educación University of Washington University of California, Los Angeles Harvard University Johns Hopkins University

About

Javier R. Lama is an author at Asociación Civil Impacta Salud y Educación specializing in social sciences, sexual health, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Social Sciences	17	18	678
2	Medicine	15	17	2.5K
3	Public Health	10	10	536
4	Engineering	1	1	60
5	Cell Biology	1	1	60

Javier R. Lama

104

Publications

13.6K

Citations

H-Index

Page 1

	Year	Citations
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men Robert M. Grant, Javier R. Lama, Peter L. Anderson, New England Journal of Medicine	2010	5K
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial Susan Buchbinder, Devan V. Mehrotra, Ann Duerr, The Lancet VaccinationTest-of-concept TrialTreatment And PreventionImmunologyVaccine Trial	2008	1.7K
Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men Peter L. Anderson, David V. Glidden, Albert Liu, Science Translational Medicine	2012	1K
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis Diane V. Havlir, Michelle A. Kendall, Prudence Ive, New England Journal of Medicine	2011	538
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition Lawrence Corey, Peter B. Gilbert, Michal Juraska, New England Journal of Medicine	2021	492
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis Susan Swindells, Ritesh Ramchandani, Amita Gupta, New England Journal of Medicine	2019	347
What Drives the US and Peruvian HIV Epidemics in Men Who Have Sex with Men (MSM)? Steven M. Goodreau, Nicole Bohme Carnegie, Eric Vittinghoff, PLoS ONE	2012	343
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri, The Lancet Infectious Diseases	2021	170
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial Pedro Cahn, Jaime Andrade‐Villanueva, José Ramón Arribas, The Lancet Infectious Diseases Open LabelHuman RetrovirusAntiviral Drug DevelopmentClinical TrialsAntiviral Therapy	2014	154
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial Kathleen Mulligan, David V. Glidden, Peter L. Anderson, Clinical Infectious Diseases	2015	147

Page 1